查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
影像导引药物传输市场 - 全球及区域分析：按技术类型、应用、最终用户和区域 - 分析与预测（2025-2035 年）
市场调查报告书
商品编码
1811795

影像导引药物传输市场 - 全球及区域分析：按技术类型、应用、最终用户和区域 - 分析与预测（2025-2035 年）

Image-Guided Drug Delivery Market - A Global and Regional Analysis: Focus on Technology Type, Application, End User, and Regional Analysis - Analysis and Forecast, 2025-2035
出版日期: | 出版商: BIS Research | 英文 128 Pages | 商品交期: 1-5个工作天内

价格

影像导引药物传递是应用先进、精确和微创技术将治疗剂直接输送到目标疾病部位，例如肿瘤或神经区域。

这个创新领域代表了现代医学的模式转移，超越了传统的全身性治疗，转向更安全、更局部、特异性病人的治疗。透过将导管和插管等专用药物输送系统与MRI、CT和超音波成像平台相结合，并辅以机器人技术和人工智慧导航，影像引导药物输送使临床医生能够以卓越的精度和可控性实施基因治疗、化疗和细胞疗法。这种方法可以提高治疗效果，最大限度地降低全身毒性，缩短恢復时间，并优化医疗资源，使影像导引药物输送成为下一代精准医疗的基石。

主要市场统计数据
预测期 2025-2035
2025年评估 6580万美元
2035年的预测 9.83亿美元
复合年增长率 31.04%

市场介绍

全球影像导引药物输送市场可望大幅成长，预计到 2035 年将达到 9.83 亿美元。在导管输液系统、多孔套管和影像引导导航平台的支援下，IGDD 整合了先进的影像处理、机器人和人工智慧，以卓越的精度提供局部治疗，最大限度地降低全身毒性，并改善患者预后。

影像引导药物传输代表了现代医学的模式转移，它结合了精准的诊断成像、可控输注和即时监测，从而扩大了标靶治疗的可及性。 ClearPoint Neuro 的 SmartFlow 套管（美国首个获得 FDA 全新批准的脑内基因治疗设备）以及 TriSalus Life Sciences 的 TriNav FLX 输注系统的商业化等重要里程碑，都体现了这种颠覆性方法。同样，像荷兰皇家飞利浦的 EmboGuide 和通用电气医疗的 FlightPlan for Liver 这样的软体主导导航平台，也支援复杂肿瘤和神经外科手术朝向标准化和可重复性迈进。

北美、欧洲和日本有利的监管和报销框架，以及公共和私营部门在混合手术室、影像基础设施和介入医师培训方面不断增加的投资，进一步支持了市场扩张。北美、欧洲和亚太国家正在扩大医院容量并培养创新中心，而随着精准医疗的加速应用，印度、巴西和东南亚等新兴市场提供了尚未开发的成长潜力。

基于人工智慧的输注计画、相容MRI的手术机器人以及多模态成像等创新技术正在提升给药准确性和长期治疗效果。虽然肿瘤学仍然是主要的应用领域，但神经病学正在迅速发展，尤其是在神经胶母细胞瘤、帕金森氏症和AADC缺乏症等疾病的基因和细胞治疗方面。胃肠道和循环系统疾病领域的更广泛应用也开始拓展影像导引药物传递技术的覆盖范围。

儘管势头强劲，挑战依然存在，包括高昂的实施成本、工作流程整合的障碍以及中低收入社区的医疗资源取得不均衡。然而，随着支付方的支持日益增多，加上产学研合作的推进，这些障碍正在透过加快临床检验和降低应用门槛来稳步克服。

ClearPoint Neuro, Inc.、TriSalus Life Sciences, Inc.、RenovoRx、荷兰皇家飞利浦公司 (Koninklijke Philips NV)、通用电气医疗集团 (GE HealthCare) 和 AiM Medical Robotics 等领先公司正在塑造竞争格​​局，开发First-in-Class的设备，积累强有力的临床证据，并在肿瘤学和神经病学领域推行竞争格局。随着医疗保健越来越重视精准医疗、微创疗法和以患者为中心的护理，影像引导给药技术正处于治疗创新的前沿，有望重新定义治疗模式，改善全球患者的治疗效果。

对产业的影响

影像导引药物传递技术正在重塑肿瘤学和神经病学治疗，它能够以微创方式精准引导先进疗法的给药。基于导管的注射平台，例如 ClearPoint Neuro 的 SmartFlow 套管和 TriSalus Life Sciences 的 TriNav FLX，重新定义了程序的精准度，使药物和基因疗法能够直接作用于目标脑区和固态肿瘤。透过突破血脑障壁等障碍并确保局部药物渗透，IGDD 技术提高了疗效，降低了全身毒性，并最大限度地缩短了住院时间，使其成为下一代个人化医疗的关键推动者。

除了单一手术之外，影像导引给药正在推动整个手术生态系统和临床工作流程的创新。 MRI/CT导引导航平台、机器人系统和AI辅助注射计画工具的整合，正在实现药物定位的标准化，并实现即时治疗监测，从而拓展了难以触及的肿瘤和中枢神经系统疾病的治疗方案。这些平台正在简化临床决策，减少手术差异，并提高不同中心治疗的可重复性。

同时，设备创新者、製药公司和学术研究中心之间的策略联盟正在加速影像导引药物输送在细胞和基因治疗临床试验的应用，目前已有60多家生物製药合作伙伴利用ClearPoint Neuro的系统进行中枢神经系统标靶输送。监管支持的途径，例如SmartFlow获得FDA的从头批准和欧盟的MDR认证，加上精准注射技术报销额度的提高，正在推动其商业性发展。

从全系统层面来看，影像导引给药技术正在透过扩大先进治疗手段的可近性来提升医疗体系的韧性，尤其是在三级医院和癌症中心。对混合手术室、介入神经放射学手术室和数影像处理基础设施的投资，正在推动这些技术的扩充性；与荷兰皇家飞利浦、通用电气医疗集团和创新生物技术公司等全球领先企业的合作，正在推动影像引导给药技术（IGDD）走向主流应用。总而言之，这些进步正在重新定义医疗服务，改善病患预后，并巩固肿瘤和神经内科精准医疗的基础。

市场区隔

细分 1：按技术类型

  • 药物输送系统
  • 影像引导平台

药物输送系统 (DDS) 将继续成为全球影像导引药物输送市场中按技术类型分類的领先细分市场，到 2024 年将占据 71.79% 的市场占有率，预计 2025 年至 2035 年的复合年增长率将达到 30.87%。套管针、多孔导管和压力输注系统等关键细分市场因其直接的治疗作用、经过验证的临床效用以及克服血脑障壁和肿瘤内药物渗透等挑战的能力而贡献最大。 DDS 占据主导地位，因为它们在实现先进疗法的靶向传递、高效治疗以及在肿瘤学和神经病学试验中的广泛应用方面发挥着重要作用。

相较之下，ClearPoint Navigation、Philips EmboGuide 和 GE FlightPlan for Liver 等影像引导平台透过改进供血血管检测、提高瞄准精度和标准化程序，正在经历快速增长。目前，IGP 市场规模较小，但随着临床工作流程需要更先进的影像集成，其份额预计将扩大。

细分2：按应用

  • 肿瘤学
  • 神经
  • 其他的

按应用划分，全球影像导引药物传输市场由肿瘤学领域主导，2024 年占 76.44% 的市场。受全球癌症发生率上升以及肝癌、胰腺癌和头颈癌等癌症对精准医疗的需求推动，预计肿瘤学领域将保持主导地位直至 2035 年。动脉内输注平台和栓塞软体已被证明能够将局部药物浓度提高 100 倍（与静脉途径相比），减少全身副作用并强化肿瘤学作为关键驱动力。神经病学是成长最快的领域，由 FDA 和 CE 认证的技术提供支持，例如 SmartFlow 套管、神经输注和多孔导管，这些技术可实现针对中枢神经系统的靶向药物输送，用于治疗胶质母细胞瘤、帕金森氏症和 AADC 缺乏症等疾病。

细分 3：按最终用户

  • 医院
  • 製药和生物技术公司
  • 委外研发机构（CRO）
  • 科学研究院所及大学

从终端用户来看，全球影像导引给药市场将由医院主导，到2024年将占91.30%的市占率。配备混合手术室、先进影像设备以及专业神经外科和肿瘤科团队的医院，将继续成为影像导引给药系统（IGDD）应用的主要枢纽。医院能够执行颅内注射和定向肿瘤治疗等大量复杂手术，这增强了其优势，随着下一代疗法在临床实践中的应用，预计其应用将进一步扩大。

细分4：按地区

  • 北美洲
    • 美国
    • 加拿大
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 其他的
  • 亚太地区
    • 日本
    • 印度
    • 中国
    • 澳洲
    • 韩国
    • 其他的
  • 其他地区

受中国高疾病负担、国内创新和影像基础设施建设的推动，亚太地区影像引导给药市场正在不断扩张。日本和韩国凭藉强大的保险支持以及先进的肿瘤和神经病学中心，正在推动该技术的普及；而印度庞大但渗透率较低的市场则因需求增长和本土创新而蓬勃发展。澳洲受益于强大的保险报销体系和私人应用，而新加坡、香港和马来西亚则在都市区提供了利基市场机会。相较之下，印尼、越南和菲律宾则面临基础设施和资金筹措的挑战。总体而言，亚太地区的成长将取决于创新、可负担性和公平的可近性。

影像导引药物传输市场的最新趋势

  • 2025 年 8 月，ClearPoint Neuro, Inc. 报告称，该公司使用 FDA 批准的 SmartFlow Neuro Cannula 在美国首次商业性交付 KEBILIDI（AADC 缺乏症基因疗法），标誌着临床应用迈出了关键一步。
  • 2025年6月，TriSalus Life Sciences, Inc. 推出了 TriNavFLX 输液系统，这是其 PEDD（压力驱动药物输送）系列的新产品。该系统的远端长度是先前型号的两倍，且更加灵活，使其能够在曲折的血管中平稳导航。桌上型测试表明，与标准 TriNav 相比，导航力降低了 28%。
  • 2025年5月，ClearPoint Neuro, Inc.与Oberland Capital签订了高达1.1亿美元的结构化融资协议，其中包括票据融资和股权部分。
  • 2025年4月，约翰霍普金斯医院加入了RenovoRx的TIGeR-PaC试验，招募局部晚期胰臟癌(LAPC)患者。本试验将评估RenovoRx的RenovoCath装置引导的动脉Gemcitabine(IAG)注射与标准静脉化疗比较。此次加入将增强该试验的有效性，该试验的目标是到2025年完成全部患者入组。
  • 2025年4月，ClearPoint Neuro, Inc. 发布了 ClearPoint 导航软体 3.0 版，这是第一个专为标准手术室设计的完整端对端 ClearPoint 导航解决方案。它引入了全新的 iCT 导引工作流程，无需 MRI 基础设施即可实现高精度脑部导航。

需求——驱动因素、挑战、机会

市场驱动因素

  • 个人化医疗需求不断成长

个人化医疗日益增长的需求正迅速推动影像引导药物输送市场的发展，强调了根据个别患者情况量身定制精准标靶治疗的必要性。在肿瘤学和神经病学等领域，个人化医疗根据基因和疾病特异性特征调整治疗方案，以确保最有效的治疗结果，同时最大限度地减少副作用。影像引导药物传递技术在这一转变中发挥关键作用，它能够将药物精确、局部靶向到特定的身体部位，从而提高治疗性介入的精准度。 2024 年发表在《药理学研究》上的一项题为「药物传递系统中的生技药品、治疗诊断学和个人化医疗」的研究强调了影像引导药物传递在治疗诊断学领域的作用，而治疗诊断学是个人化医疗的关键组成部分。这种方法利用先进的影像技术精确引导和监测治疗剂，确保药物在目标疾病部位的精确定位。

透过最大限度地减少脱靶效应，这项技术显着改善了治疗效果。此外，治疗方案可即时调整，优化药物输送，确保精准剂量到达正确部位。这种精准性在前列腺癌和神经退化性疾病等领域尤其重要，精准药物标靶可显着改善患者预后。

  • 慢性病盛行率上升

市场限制

  • 设备购置成本高

影像导引给药装置的高成本仍然是这项创新技术广泛应用和市场成长的一大障碍，尤其是在中低收入国家。这些系统高度依赖先进的影像技术，例如核磁共振成像 (MRI)、CT 和萤光透视，这些技术对于手术和给药过程中的精确导航至关重要。然而，这些技术的经济负担也相当沉重。例如，核磁共振造影系统的价格在 13 万至 70 万美元之间，此外还有持续的维护、软体更新和专业人员培训成本。高昂的初始成本和持续的营运成本对医院构成了重大障碍，尤其是在资源受限的环境中，由于医疗预算有限，难以证明投资的合理性。

因此，此财务障碍不仅限制了影像导引给药系统在临床环境中的应用，也阻碍了整体市场的扩张。新兴国家中预算有限的小型医疗保健机构通常无力投资此类技术。这导致影像导引给药技术集中在少数资金充足的医院，限制了其广泛应用及其对医疗资源匮乏地区患者照护的潜在影响。因此，这些地区的患者无法享受更精准、更有针对性的给药服务，而这种服务在癌症治疗和需要高精度的专科医疗程序中尤其有用。

市场机会

  • 将人工智慧融入影像引导药物输送

影像导引药物传递系统与人工智慧 (AI) 的结合已成为癌症治疗的一项革命性进步，为药物传递和监测的精确度、准确度和效率带来了可喜的提升。 AI 加速了影像分析过程，能够识别医学扫描中的细微模式，从而优化药物向肿瘤部位的输送。这项创新使临床医生能够以前所未有的精确度瞄准肿瘤，确保适量的药物到达肿瘤，同时最大限度地减少对健康组织的暴露。即时监测是癌症个人化治疗的关键组成部分，而 AI 能够持续追踪体内药物和奈米颗粒的行为，从而大大增强了即时监测的能力。 AI 演算法监测药物分布并动态调整药物传递过程，以更可靠地瞄准癌细胞。透过提供这种程度的监测，AI 有助于提高治疗的精确度和结果，为临床医生提供做出更明智决策所需的工具。 AI 的影响不仅限于增强影像和监测，还扩展到个人化治疗计划。

市场趋势

成像与药物传输的整合

影像与标靶给药的融合是现代医学的关键趋势，从根本上重塑了神经病学和肿瘤学的治疗方法。这项模式转移由多项关键进展的汇聚推动，包括重要的监管里程碑、不断扩大的临床应用、创新新设备的推出以及强劲的市场发展势头。这种融合对影像引导给药市场产生了深远的影响，使其迅速从以研究为重点的小众领域扩展至主流临床应用。这一转变得益于美国食品药物管理局（FDA）对ClearPoint Neuro, Inc.的SmartFlow Neuro Cannula等设备的重新审批，这为类似技术检验了清晰的监管途径，降低了投资者风险并加速了商业化进程。在临床层面，即时影像和专用导管的使用提供了前所未有的精准度，确保更高浓度的治疗药物到达目标部位，同时保护健康组织。

这不仅提高了治疗效果并降低了毒性，还能创造出标准化、可重复的工作流程，进而提高医院的效率和成本效益。市场上正在涌现大量新型专用设备，例如 RenovoRx 的 RenovoCath 和 TriSalus Life Sciences 的 TriNav FLX，推动了靶向肿瘤治疗和中枢神经系统给药等高成长领域的发展。最终，专用给药设备与影像导引导航的结合将创造新的治疗标准，从而减少併发症，提高手术成功率，并改善这些重要治疗领域的患者预后。

成长/行销策略：透过提供全面的市场分析和识别关键的成长机会，公司能够获得制定有针对性的行销策略和有效扩大其市场占有率的知识。

竞争策略：透过对竞争格局的彻底分析，我们了解您的竞争对手的优势和劣势，并帮助您制定有效的策略以在市场上获得竞争优势。

监管和合规策略：提供有关不断发展的法律规范、核准和行业指南的最新信息，以使公司能够保持合规并加快新型图像引导药物输送的市场进入。

投资和业务扩大策略：透过分析市场趋势、资金筹措模式和合作机会，我们帮助公司做出明智的投资决策并确定业务成长的潜在併购机会。

公司简介的选择是基于对公司覆盖范围、产品系列、市场渗透率的分析以及从主要专家收集的意见。

影像导引药物传输市场的主要企业包括全球医疗设备和影像处理公司，它们为肿瘤学和神经病学领域提供广泛的药物传输系统和影像引导平台。 ClearPoint Neuro, Inc.、荷兰皇家飞利浦公司和通用电气医疗集团 (GE Healthcare) 等老字型大小企业凭藉其用于介入肿瘤学和中枢神经系统治疗的整合式 MRI 导引导航、输液套管和血管映射软体产品组合占据主导地位。

创新企业正在开发多孔导管、压力驱动输液系统和人工智慧辅助导航软体，以提高输送准确性和治疗效果。 TriSalus Life Sciences 和 RenovoRx 等公司正在率先推出基于导管的肿瘤学平台，而 AiM Medical Robotics 等公司则正在开发用于神经外科的兼容 MRI 的手术机器人。 Neurochase 和 Infusion Therapeutics 等新兴企业正在推出用于直接脑部输液的新型对流增强输送系统。

新兴企业和区域性公司也正在贡献经济高效的注射技术、可携式导航工具以及专业的药物-器械组合，以满足新兴市场尚未满足的需求。这些公司共同推动创新，扩大临床可及性，并将影像引导药物输送确立为精准引导、微创治疗传递的基石。

该市场上知名的知名公司包括：

  • ClearPoint Neuro, Inc.
  • TriSalus Life Sciences, Inc.
  • GE Healthcare
  • Koninklijke Philips NV
  • RenovoRx Inc.

目录

执行摘要

第一章市场：产业展望

  • 竞争格局
  • 产业展望
  • 市场动态

第二章 技术

  • 概述
  • 药物输送系统
  • 影像引导平台

第三章 应用

  • 概述
  • 肿瘤学
  • 神经病学
  • 其他的

第四章 最终用户

  • 概述
  • 医院
  • 科学研究机构和大学
  • 製药和生物技术公司
  • CRO

第五章 区域

  • 区域摘要
  • 北美洲
  • 欧洲
  • 亚太地区
  • 其他地区

第六章 市场-公司简介

  • 公司简介
    • ClearPoint Neuro, Inc.
    • AiM Medical Robotics
    • TriSalus Life Sciences
    • RenovoRx Inc.
    • Renishaw plc.
    • Occam Design
    • Infuseon Therapeutics Inc
    • Neurochase
    • GE HealthCare
    • Koninklijke Philips NV

第七章调查方法

Product Code: BHL3241SA

This report can be delivered within 1 working day.

Introduction of Image-Guided Drug Delivery

Image-Guided Drug Delivery applies advanced, precision-driven, minimally invasive techniques to deliver therapeutics directly to targeted disease sites, including tumors and neurological regions. This innovative field represents a paradigm shift in modern medicine, moving beyond conventional systemic therapies toward safer, more localized, and patient-specific interventions. By combining specialized drug delivery systems such as catheters and cannulae with MRI, CT, and ultrasound-based imaging platforms, augmented by robotics and AI-driven navigation, image-guided drug delivery enables clinicians to administer gene therapies, chemotherapeutics, and cell-based treatments with exceptional accuracy and control. This approach improves therapeutic efficacy, minimizes systemic toxicity, shortens recovery times, and optimizes healthcare resources, positioning image-guided drug delivery as a cornerstone of next-generation precision medicine.

KEY MARKET STATISTICS
Forecast Period2025 - 2035
2025 Evaluation$65.8 Million
2035 Forecast$983.0 Million
CAGR31.04%

Market Introduction

The global image-guided drug delivery market is expected to witness significant growth, projected to reach $983.0 million by 2035, driven by the escalating global burden of cancer, neurological disorders, and other chronic diseases that demand safer, more precise, and less invasive therapeutic approaches. Anchored in catheter-based infusion systems, multiport cannulae, and image-guided navigation platforms, IGDD integrates advanced imaging, robotics, and AI to deliver localized therapies with superior accuracy, minimized systemic toxicity, and improved patient outcomes.

Image-guided drug delivery represents a paradigm shift in modern medicine, combining imaging precision, controlled infusion, and real-time monitoring to expand access to targeted therapies. Key milestones, such as the FDA De Novo clearance of ClearPoint Neuro's SmartFlow Cannula, the first U.S.-approved device for intracerebral gene therapy-and the commercial launch of TriSalus Life Sciences' TriNav FLX infusion system, have validated these disruptive approaches. Similarly, software-driven navigation platforms such as Koninklijke Philips' EmboGuide and GE HealthCare's FlightPlan for Liver underscore the move toward standardization and reproducibility in complex oncology and neurology procedures.

Market expansion is further supported by favorable regulatory and reimbursement frameworks in North America, Europe, and Japan, coupled with increasing investments from the public and private sectors in hybrid operating suites, imaging infrastructure, and training for interventional specialists. Countries across North America, Europe, and Asia-Pacific are scaling hospital capacity and fostering innovation hubs, while emerging markets such as India, Brazil, and Southeast Asia present untapped potential for growth as precision medicine adoption accelerates.

Technological convergence is a key accelerator, with innovations in AI-assisted infusion planning, MRI-compatible surgical robotics, and multimodal imaging enhancing both delivery accuracy and long-term therapeutic outcomes. While oncology remains the dominant application, neurology is rapidly expanding, particularly in gene and cell therapy delivery for conditions such as glioblastoma, Parkinson's disease, and AADC deficiency. Broader applications in gastrointestinal and cardiovascular disorders are also beginning to extend the scope of image-guided drug delivery technologies.

Despite strong momentum, challenges such as high acquisition costs, workflow integration barriers, and uneven access in low- and middle-income regions remain. However, growing payer support, coupled with industry-academic-biopharma collaborations, is steadily overcoming these hurdles by accelerating clinical validation and lowering barriers to adoption.

Leading players such as ClearPoint Neuro, Inc., TriSalus Life Sciences, Inc., RenovoRx, Koninklijke Philips N.V., GE HealthCare, and AiM Medical Robotics are shaping the competitive landscape, advancing first-in-class devices, building robust clinical evidence, and pursuing commercialization strategies across oncology and neurology. As healthcare increasingly emphasizes precision medicine, minimally invasive delivery, and patient-centric care, image-guided drug delivery is positioned at the forefront of therapeutic innovation, set to redefine treatment paradigms and improve outcomes for patients worldwide.

Industrial Impact

Image-guided drug delivery is reshaping therapeutic care in oncology and neurology by enabling minimally invasive, precision-guided administration of advanced treatments. Catheter-based infusion platforms such as ClearPoint Neuro's SmartFlow Cannula and TriSalus Life Sciences' TriNav FLX have redefined procedural accuracy, allowing direct drug and gene therapy delivery into targeted brain regions or solid tumors. By overcoming barriers such as the blood-brain barrier and ensuring localized drug penetration, IGDD technologies are improving efficacy, reducing systemic toxicity, and minimizing hospital stays-positioning them as critical enablers of next-generation personalized medicine.

Beyond individual procedures, image-guided drug delivery is fostering innovation across procedural ecosystems and clinical workflows. Integration of MRI/CT-guided navigation platforms ,robotic systems, and AI-assisted infusion planning tools is standardizing drug placement, enabling real-time therapy monitoring, and expanding treatment options for hard-to-reach tumors and CNS disorders. These platforms streamline clinical decision-making, reduce procedural variability, and make therapies more reproducible across institutions.

Simultaneously, strategic collaborations between device innovators, pharmaceutical companies, and academic research centers are accelerating the adoption of image-guided drug delivery in cell and gene therapy trials, with >60 biopharma partners already leveraging ClearPoint Neuro's systems for CNS-targeted delivery. Supportive regulatory pathways, such as the FDA's De Novo clearance of SmartFlow and EU MDR certifications, coupled with increasing reimbursement for precision infusion procedures, are driving commercial momentum.

At a system-wide level, Image-guided drug delivery is enhancing healthcare resilience by broadening access to advanced therapies, particularly in tertiary-care hospitals and cancer centers. Investments in hybrid ORs, neuro-interventional suites, and digital imaging infrastructure are enabling scalability of these technologies, while partnerships with global leaders such as Koninklijke Philips N.V., GE HealthCare, and innovative biotech firms are pushing IGDD toward mainstream adoption. Collectively, these advancements are redefining treatment delivery, improving patient outcomes, and strengthening the foundations of precision therapy in oncology and neurology.

Market Segmentation:

Segmentation 1: By Technology Type

  • Drug-Delivery Systems
  • Image-Guided Platforms

Drug-Delivery Systems (DDS) remain the leading segment by technology type in the global image-guided drug delivery market, holding 71.79% market share in 2024, with a projected CAGR of 30.87% during 2025-2035. Key subsegmentssuch as cannulae, multiport catheters, and pressure-enabled infusion systems drive the largest contributions due to their direct therapeutic role, proven clinical utility, and ability to overcome challenges such as the blood-brain barrier or intratumoral drug penetration. DDS dominate because of their essential role in enabling targeted delivery of advanced therapies, higher efficacy, and wider adoption in both oncology and neurology trials.

In contrast, Image-Guided Platforms including ClearPoint Navigation, Philips EmboGuide, and GE FlightPlan for Liver are growing rapidly as they improve feeder-vessel detection, enhance targeting accuracy, and standardize procedures. While smaller today, IGPs are expected to capture increasing share as clinical workflows demand greater imaging integration.

Segmentation 2: By Application

  • Oncology
  • Neurology
  • Others

Based on application, the global image-guided drug delivery market was led by the Oncology segment, which accounted for 76.44% share in 2024. Oncology is projected to maintain dominance through 2035 due to the rising global cancer burden and the demand for precision therapies in hepatic, pancreatic, and head & neck cancers. Intra-arterial infusion platforms and embolization software have demonstrated the ability to improve local drug concentration by up to 100X compared to IV routes, reducing systemic side effects and reinforcing oncology as the primary growth driver. Neurology is the fastest-growing segment, supported by FDA and CE-cleared technologies such as SmartFlow Cannula, neuroinfuse, and multiport catheters that enable targeted CNS delivery for conditions like glioblastoma, Parkinson's, and AADC deficiency.

Segmentation 3: By End User

  • Hospitals
  • Pharmaceutical & Biotechnology Companies
  • Contract Research Organizations (CROs)
  • Research Institutes & Universities

Based on end user, the global image-guided drug delivery market was led by the Hospitals segment, which held a 91.30% share in 2024. Hospitals remain the primary hubs for IGDD adoption, equipped with hybrid operating suites, advanced imaging modalities, and specialized neurosurgical and oncology teams. Their ability to perform high-volume, complex procedures such as intracranial infusions and liver-directed oncology therapies supports their dominance, with adoption expected to grow as more next-generation therapies enter clinical practice.

Segmentation 4: By Region

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Rest-of-Europe
  • Asia-Pacific
    • Japan
    • India
    • China
    • Australia
    • South Korea
    • Rest-of-Asia-Pacific
  • Rest-of-the-World

The Image-Guided Drug Delivery market in the Asia-Pacific region is expanding, led by China's high disease burden, domestic innovation, and growing imaging infrastructure. Japan and South Korea drive adoption through strong insurance support and advanced oncology and neurology centers, while India's vast, underpenetrated market is gaining momentum with rising demand and local innovation. Australia benefits from strong reimbursement and private adoption, whereas Singapore, Hong Kong, and Malaysia offer niche urban opportunities. In contrast, Indonesia, Vietnam, and the Philippines face infrastructure and funding challenges. Overall, growth in APAC hinges on innovation, affordability, and equitable access.

Recent Developments in the Image-Guided Drug Delivery Market

  • In August 2025, ClearPoint Neuro, Inc. reported the first-ever commercial delivery of KEBILIDI (AADC deficiency gene therapy) in the U.S. using its FDA-authorized SmartFlow Neuro Cannula, marking a pivotal step in clinical implementation.
  • In June 2025, TriSalus Life Sciences, Inc. rolled out the TriNavFLX Infusion System, a new addition to its Pressure Enabled Drug Delivery (PEDD) line. The system's distal end is twice as long and more flexible than previous models, enabling smooth navigation through tortuous vessels. In benchtop testing, it reduced navigation force by 28% compared to the standard TriNav.
  • In May 2025, ClearPoint Neuro, Inc. entered into a structured financing agreement with Oberland Capital for up to $110 million, including note financing and equity components.
  • In April 2025, Johns Hopkins Medicine joined RenovoRx's TIGeR-PaC trial, enrolling patients with locally advanced pancreatic cancer (LAPC). The trial evaluates RenovoRx's intra-arterial gemcitabine (IAG) delivery via the RenovoCath device, comparing it to standard intravenous chemotherapy. This addition strengthens the trial, aiming for full enrollment by 2025.
  • In April 2025, ClearPoint Neuro, Inc. released ClearPoint Navigation Software Version 3.0, the first full end-to-end ClearPoint navigation solution specifically designed for standard operating rooms. It introduces a new iCT-guided workflow, enabling high-precision brain navigation without requiring MRI infrastructure.

Demand -Drivers, Challenges, and Opportunities

Market Demand Drivers:

  • Increased Demand for Personalized Medicine

The growing demand for personalized medicine is rapidly driving the evolution of the image-guided drug delivery market, as it emphasizes the necessity for precise, targeted therapies tailored to individual patient profiles. In fields such as oncology and neurology, personalized medicine seeks to adapt treatments based on genetic and disease-specific characteristics, ensuring the most effective outcomes with minimal side effects. Image-guided drug delivery technologies play a pivotal role in this transformation by enabling accurate, localized targeting of medications to specific body regions, thereby enhancing the precision of therapeutic interventions. A 2024 study published in Pharmacological Research, titled "Biologics, Theranostics, and Personalized Medicine in Drug Delivery Systems," underscored the role of image-guided drug delivery in the realm of theranostics, a critical component of personalized medicine. This approach utilizes advanced imaging technologies to precisely direct and monitor therapeutics, ensuring accurate drug localization at targeted disease sites.

By minimizing off-target effects, this technique significantly enhances therapeutic outcomes. Moreover, the ability to adjust treatment in real-time optimizes drug delivery, ensuring that the right dosage reaches the right location. This precision is especially impactful in areas such as prostate cancer and neurodegenerative diseases, where accurate drug targeting can markedly improve patient outcomes.Some of the other driving factors include:

  • Rising Prevalence of Chronic Diseases

Note: All of the above factors will be evaluated in detail in the report.

Market Restraints:

  • High Acquisition Cost of the Instruments

The high cost of equipment for image-guided drug delivery presents a substantial barrier to the widespread adoption and market growth of this innovative technology, especially in low- and middle-income countries. These systems rely heavily on advanced imaging technologies such as MRI, CT, and fluoroscopy, which are essential for precise navigation during surgeries and drug delivery. However, the financial burden of these technologies is considerable. For instance, MRI machines can cost between $130,000 and $700,000, with additional ongoing expenses for maintenance, software updates, and specialized personnel training. The combination of these high upfront costs and continuous operational expenses creates a significant hurdle for hospitals, particularly in resource-constrained settings, making it difficult to justify the investment when healthcare budgets are limited.

As a result, this financial barrier not only limits the adoption of image-guided drug delivery systems in clinical environments but also hinders the overall expansion of the market. Smaller healthcare providers in emerging economies, where budgets are stretched thin, often cannot afford to invest in such technology, which may be perceived as non-essential in comparison to other immediate healthcare needs. This leads to a concentration of image-guided drug delivery technology in a small number of well-funded hospitals, restricting its broader application and diminishing its potential impact on patient care in underserved regions. Consequently, patients in these areas miss out on the benefits of more precise, targeted drug delivery, which is particularly valuable in cancer treatment and other specialized medical procedures requiring high levels of accuracy.

Market Opportunities:

  • Integration of Artificial Intelligence in Image-Guided Drug Delivery

The integration of Artificial Intelligence (AI) with image-guided drug delivery systems has emerged as a transformative advancement in cancer therapy, offering promising improvements in the accuracy, precision, and efficiency of drug delivery and monitoring. AI accelerates the process of image analysis, enabling the identification of subtle patterns within medical scans that optimize drug delivery to tumor sites. This innovation allows clinicians to target tumors with unprecedented precision, ensuring that the right amount of drug reaches the tumor while minimizing exposure to healthy tissue. Real-time monitoring, a critical component of personalized cancer care, is significantly enhanced through AI's ability to continuously track the behavior of drugs and nanoparticles within the body. AI algorithms monitor drug distribution and adjust the delivery process dynamically, ensuring better targeting of tumor cells. By providing this level of monitoring, AI contributes to improved treatment precision and outcomes, offering clinicians the tools necessary for more informed decision-making. AI's impact extends beyond the enhancement of imaging and monitoring to the personalization of treatment plans.

Market Trends:

Integration of Imaging with Targeted Drug Delivery

The integration of imaging with targeted drug delivery is a pivotal trend in modern medicine, fundamentally reshaping therapeutic approaches in both neurology and oncology. This paradigm shift is driven by a convergence of key developments, including significant regulatory milestones, growing clinical adoption, the launch of innovative new devices, and robust market momentum. This convergence is profoundly impacting the image-guided drug delivery market, transforming it from a niche, research-focused field into a rapidly expanding sector for mainstream clinical applications. This shift is fueled by the FDA's De Novo clearance of devices such as ClearPoint Neuro's SmartFlow Neuro Cannula, which validates a clear regulatory pathway for similar technologies, thereby reducing risk for investors and accelerating commercialization. On a clinical level, the use of real-time imaging and specialized catheters allows for unprecedented precision, ensuring a higher concentration of the therapeutic agent reaches the target site while sparing healthy tissue.

This not only improves treatment efficacy and reduces toxicity but also creates standardized, repeatable workflows that are more efficient and cost-effective for hospitals. The market is seeing a surge of new, purpose-built devices such as RenovoRx's RenovoCath and TriSalus Life Sciences' TriNav FLX, which are driving high-growth segments in targeted oncology and CNS delivery. Ultimately, the convergence of specialized delivery devices and image-guided navigation is creating a new standard of care, leading to reduced complications, higher procedure volumes, and improved patient outcomes in these critical therapeutic areas.

How can this report add value to an organization?

Product/Innovation Strategy: The report offers in-depth insights into the latest technological advancements in Image-Guided Drug Delivery, enabling organizations to drive innovation and develop cutting-edge products tailored to market needs.

Growth/Marketing Strategy: By providing comprehensive market analysis and identifying key growth opportunities, the report equips organizations with the knowledge to craft targeted marketing strategies and expand their market presence effectively.

Competitive Strategy: The report includes a thorough competitive landscape analysis, helping organizations understand their competitors' strengths and weaknesses and allowing them to strategize effectively to gain a competitive edge in the market.

Regulatory and Compliance Strategy: It provides updates on evolving regulatory frameworks, approvals, and industry guidelines, ensuring organizations stay compliant and accelerate market entry for new Image-Guided Drug Delivery

Investment and Business Expansion Strategy: By analyzing market trends, funding patterns, and partnership opportunities, the report assists organizations in making informed investment decisions and identifying potential M&A opportunities for business growth.

Methodology

Key Considerations and Assumptions in Market Engineering and Validation

  • The base year considered for the calculation of the market size is 2024. A historical year analysis has been done for the period FY2023. The market size has been estimated for FY2024 and projected for the period FY2025-FY2035.
  • The scope of this report has been carefully derived based on extensive interactions with experts and stakeholders across leading companies and research institutions worldwide. This report provides a comprehensive market analysis of robotics and non-robotics within the Image-Guided Drug Delivery market.
  • Revenues of the companies have been referenced from their annual reports for FY2023 and FY2024. For private companies, revenues have been estimated based on factors such as inputs obtained from primary research, funding history, market collaborations, and operational history.
  • The market has been mapped based on the available Image-Guided Drug Delivery products. All the key companies with significant offerings in this field have been considered and profiled in this report.

Primary Research:

The primary sources involve industry experts in Image-Guided Drug Delivery, including the market players offering products and services. Resources such as CEOs, vice presidents, marketing directors, and technology and innovation directors have been interviewed to obtain and verify both qualitative and quantitative aspects of this research study.

The key data points taken from the primary sources include:

  • Validation and triangulation of all the numbers and graphs
  • Validation of the report's segmentation and key qualitative findings
  • Understanding the competitive landscape and business model
  • Current and proposed production values of a product by market players
  • Validation of the numbers of the different segments of the market in focus
  • Percentage split of individual markets for regional analysis

Secondary Research

Open Sources

  • Certified publications, articles from recognized authors, white papers, directories, and major databases, among others
  • Annual reports, SEC filings, and investor presentations of the leading market players
  • Company websites and detailed study of their product portfolio
  • Gold standard magazines, journals, white papers, press releases, and news articles
  • Paid databases

The key data points taken from the secondary sources include:

  • Segmentations and percentage shares
  • Data for market value
  • Key industry trends of the top players of the market
  • Qualitative insights into various aspects of the market, key trends, and emerging areas of innovation
  • Quantitative data for mathematical and statistical calculations

Key Market Players and Competition Synopsis

Profiled companies have been selected based on inputs gathered from primary experts, as well as analyzing company coverage, product portfolio, and market penetration.

Key players in the image-guided drug delivery market include global medical device and imaging companies offering a broad range of drug delivery systems and image-guided platforms for oncology and neurology. Established firms such as ClearPoint Neuro, Inc., Koninklijke Philips N.V., and GE HealthCare dominate with portfolios spanning MRI-guided navigation, infusion cannulae, and vessel-mapping software integrated into interventional oncology and CNS therapies.

Innovators are developing multiport catheters, pressure-enabled infusion systems, and AI-assisted navigation software to improve delivery accuracy and therapeutic outcomes. Companies like TriSalus Life Sciences and RenovoRx are pioneering catheter-based oncology platforms, while AiM Medical Robotics and others are advancing MRI-compatible surgical robots for neurosurgical delivery. Emerging players, including Neurochase and Infuseon Therapeutics, are introducing novel convection-enhanced delivery systems for direct brain infusion.

Start-ups and regional firms are also contributing with cost-effective infusion technologies, portable navigation tools, and specialized drug-device combinations targeting unmet needs in emerging markets. Collectively, these companies are driving innovation, expanding clinical access, and establishing image-guided drug delivery as a cornerstone of precision-guided, minimally invasive therapeutic delivery.

Some prominent names established in this market are:

  • ClearPoint Neuro, Inc.
  • TriSalus Life Sciences, Inc.
  • GE Healthcare
  • Koninklijke Philips N.V.
  • RenovoRx Inc.

Table of Contents

Executive Summary

Scope and Definition

1 Market: Industry Outlook

  • 1.1 Competitive Landscape
  • 1.2 Industry Outlook
    • 1.2.1 Trends, Drivers, Challenges, and Opportunities: Current and Future Impact Assessment, 2024-2035
    • 1.2.2 Market Trends
      • 1.2.2.1 Integration of Imaging with Targeted Drug Delivery
    • 1.2.3 Advancements in Image-Guided Drug Delivery
    • 1.2.4 Future Direction and Emerging Technologies in Image-Guided Drug Delivery
  • 1.3 Market Dynamics
    • 1.3.1 Impact Analysis
    • 1.3.2 Market Driver
      • 1.3.2.1 Increased Demand for Personalized Medicine
      • 1.3.2.2 Rising Prevalence of Chronic Diseases
      • 1.3.2.3 Technological Advancements in Image-Guided Drug Delivery
    • 1.3.3 Market Restraint
      • 1.3.3.1 High Acquisition Cost of the Instruments
    • 1.3.4 Market Opportunity
      • 1.3.4.1 Integration of Artificial Intelligence in Image-Guided Drug Delivery

2 Technology

  • 2.1 Overview
  • 2.2 Drug Delivery Systems
  • 2.3 Image-Guided Platforms

3 Application

  • 3.1 Overview
  • 3.2 Oncology
  • 3.3 Neurology
  • 3.4 Others

4 End User

  • 4.1 Overview
  • 4.2 Hospitals
  • 4.3 Research Institutes and Universities
  • 4.4 Pharmaceutical and Biotechnology Companies
  • 4.5 Contract Research Organizations (CROs)

5 Region

  • 5.1 Regional Summary
  • 5.2 North America
    • 5.2.1 Regional Overview
    • 5.2.2 Driving Factors for Market Growth
    • 5.2.3 Factors Challenging the Market
    • 5.2.4 By Technology Type
    • 5.2.5 By Application
    • 5.2.6 By End User
    • 5.2.7 By Country
      • 5.2.7.1 U.S.
    • 5.2.8 By Technology Type
    • 5.2.9 By Application
    • 5.2.10 By End User
      • 5.2.10.1 Canada
    • 5.2.11 By Technology Type
    • 5.2.12 By Application
    • 5.2.13 By End User
  • 5.3 Europe
    • 5.3.1 Regional Overview
    • 5.3.2 Driving Factors for Market Growth
    • 5.3.3 Factors Challenging the Market
    • 5.3.4 By Technology Type
    • 5.3.5 By Application
    • 5.3.6 By End User
    • 5.3.7 By Country
      • 5.3.7.1 U.K.
    • 5.3.8 By Technology Type
    • 5.3.9 By Application
    • 5.3.10 By End User
      • 5.3.10.1 Germany
    • 5.3.11 By Technology Type
    • 5.3.12 By Application
    • 5.3.13 By End User
      • 5.3.13.1 France
    • 5.3.14 By Technology Type
    • 5.3.15 By Application
    • 5.3.16 By End User
      • 5.3.16.1 Italy
    • 5.3.17 By Technology Type
    • 5.3.18 By Application
    • 5.3.19 By End User
      • 5.3.19.1 Spain
    • 5.3.20 By Technology Type
    • 5.3.21 By Application
    • 5.3.22 By End User
      • 5.3.22.1 Rest-of-Europe
    • 5.3.23 By Technology Type
    • 5.3.24 By Application
    • 5.3.25 By End User
  • 5.4 Asia-Pacific
    • 5.4.1 Regional Overview
    • 5.4.2 Driving Factors for Market Growth
    • 5.4.3 Factors Challenging the Market
    • 5.4.4 By Technology Type
    • 5.4.5 By Application
    • 5.4.6 By End User
    • 5.4.7 By Country
      • 5.4.7.1 Japan
    • 5.4.8 By Technology Type
    • 5.4.9 By Application
    • 5.4.10 By End User
      • 5.4.10.1 China
    • 5.4.11 By Technology Type
    • 5.4.12 By Application
    • 5.4.13 By End User
      • 5.4.13.1 India
    • 5.4.14 By Technology Type
    • 5.4.15 By Application
    • 5.4.16 By End User
      • 5.4.16.1 Australia
    • 5.4.17 By Technology Type
    • 5.4.18 By Application
    • 5.4.19 By End User
      • 5.4.19.1 South Korea
    • 5.4.20 By Technology Type
    • 5.4.21 By Application
    • 5.4.22 By End User
      • 5.4.22.1 Rest-of-Asia-Pacific
    • 5.4.23 By Technology Type
    • 5.4.24 By Application
    • 5.4.25 By End User
  • 5.5 Rest-of-the-World
    • 5.5.1 Regional Overview
    • 5.5.2 Driving Factors for Market Growth
    • 5.5.3 Factors Challenging the Market
    • 5.5.4 By Technology Type
    • 5.5.5 By Application
    • 5.5.6 By End User
    • 5.5.7 Latin America
      • 5.5.7.1 Regional Overview
      • 5.5.7.2 Driving Factors for Market Growth
      • 5.5.7.3 Factors Challenging the Market
    • 5.5.8 Middle East and Africa
      • 5.5.8.1 Regional Overview
      • 5.5.8.2 Driving Factors for Market Growth
      • 5.5.8.3 Factors Challenging the Market
    • 5.5.9 Rest-of-the-World Country Overview

6 Markets - Company Profiles

  • 6.1 Company Profiles
    • 6.1.1 ClearPoint Neuro, Inc.
      • 6.1.1.1 Overview
      • 6.1.1.2 Top Products/Product Portfolio
      • 6.1.1.3 Top Competitors
      • 6.1.1.4 Target Customers
      • 6.1.1.5 Key Personnel
      • 6.1.1.6 Analyst View
      • 6.1.1.7 ClearPoint Neuro, Inc., Revenue ($Thousand), 2022-2024
    • 6.1.2 AiM Medical Robotics
      • 6.1.2.1 Overview
      • 6.1.2.2 Pipeline Product Portfolio
      • 6.1.2.3 Top Competitors
      • 6.1.2.4 Target Customers
      • 6.1.2.5 Key Personnel
      • 6.1.2.6 Analyst View
    • 6.1.3 TriSalus Life Sciences
      • 6.1.3.1 Overview
      • 6.1.3.2 Top Products/Product Portfolio
      • 6.1.3.3 Top Competitors
      • 6.1.3.4 Target Customers
      • 6.1.3.5 Key Personnel
      • 6.1.3.6 Analyst View
      • 6.1.3.7 TriSalus Life Sciences, Revenue ($Thousand), 2022-2024
    • 6.1.4 RenovoRx Inc.
      • 6.1.4.1 Overview
      • 6.1.4.2 Top Products/Product Portfolio
      • 6.1.4.3 Top Competitors
      • 6.1.4.4 Target Customers
      • 6.1.4.5 Key Personnel
      • 6.1.4.6 Analyst View
      • 6.1.4.7 RenovoRx Inc., Revenue ($Thousand), 2022-2024
    • 6.1.5 Renishaw plc.
      • 6.1.5.1 Overview
      • 6.1.5.2 Pipeline Product Portfolio
      • 6.1.5.3 Top Competitors
      • 6.1.5.4 Target Customers
      • 6.1.5.5 Key Personnel
      • 6.1.5.6 Analyst View
      • 6.1.5.7 Renishaw plc., Revenue ($Million), 2022-2024
    • 6.1.6 Occam Design
      • 6.1.6.1 Overview
      • 6.1.6.2 Pipeline Product Portfolio
      • 6.1.6.3 Top Competitors
      • 6.1.6.4 Target Customers
      • 6.1.6.5 Key Personnel
      • 6.1.6.6 Analyst View
    • 6.1.7 Infuseon Therapeutics Inc
      • 6.1.7.1 Overview
      • 6.1.7.2 Pipeline Product Portfolio
      • 6.1.7.3 Top Competitors
      • 6.1.7.4 Target Customers
      • 6.1.7.5 Key Personnel
      • 6.1.7.6 Analyst View
    • 6.1.8 Neurochase
      • 6.1.8.1 Overview
      • 6.1.8.2 Pipeline Product Portfolio
      • 6.1.8.3 Top Competitors
      • 6.1.8.4 Target Customers
      • 6.1.8.5 Key Personnel
      • 6.1.8.6 Analyst View
    • 6.1.9 GE HealthCare
      • 6.1.9.1 Overview
      • 6.1.9.2 Top Products/Product Portfolio
      • 6.1.9.3 Top Competitors
      • 6.1.9.4 Target Customers
      • 6.1.9.5 Key Personnel
      • 6.1.9.6 Analyst View
      • 6.1.9.7 GE HealthCare, Revenue ($Million), 2022-2024
    • 6.1.10 Koninklijke Philips N.V.
      • 6.1.10.1 Overview
      • 6.1.10.2 Top Products/Product Portfolio
      • 6.1.10.3 Top Competitors
      • 6.1.10.4 Target Customers
      • 6.1.10.5 Key Personnel
      • 6.1.10.6 Analyst View

7 Research Methodology

  • 7.1 Data Sources
    • 7.1.1 Primary Data Sources
    • 7.1.2 Secondary Data Sources
    • 7.1.3 Data Triangulation
  • 7.2 Market Estimation and Forecast

List of Figures

  • Figure 1: Global Image-Guided Drug Delivery Market (by Scenario), $Million, 2024, 2030, and 2035
  • Figure 2: Global Image-Guided Drug Delivery Market, 2024 and 2035
  • Figure 3: Top 9 Countries, Global Image-Guided Drug Delivery Market, $Million, 2024
  • Figure 4: Global Image-Guided Drug Delivery Market Snapshot
  • Figure 5: Global Image-Guided Drug Delivery Market, $Million, 2024 and 2035
  • Figure 6: Global Image-Guided Drug Delivery Market (by Technology Type), $Million, 2024, 2030, and 2035
  • Figure 7: Global Image-Guided Drug Delivery Market (by Application), $Million, 2024, 2030, and 2035
  • Figure 8: Global Image-Guided Drug Delivery Market (by End User), $Million, 2024, 2030, and 2035
  • Figure 9: Image-Guided Drug Delivery Market Segmentation
  • Figure 10: Global Image-Guided Drug Delivery Market (by Technology Type), $Million, 2024, 2030, and 2035
  • Figure 11: Global Image-Guided Drug Delivery Market (Drug Delivery Systems), $Million, 2024-2035
  • Figure 12: Global Image-Guided Drug Delivery Market (Image-Guided Platforms), $Million, 2024-2035
  • Figure 13: Global Image-Guided Drug Delivery Market (by Application), $Million, 2024, 2030, and 2035
  • Figure 14: Global Image-Guided Drug Delivery Market (Oncology), $Million, 2024-2035
  • Figure 15: Global Image-Guided Drug Delivery Market (Neurology), $Million, 2024-2035
  • Figure 16: Global Image-Guided Drug Delivery Market (Others), $Million, 2024-2035
  • Figure 17: Global Image-Guided Drug Delivery Market (by End User), $Million, 2024, 2030, and 2035
  • Figure 18: Global Image-Guided Drug Delivery Market (Hospitals), $Million, 2024-2035
  • Figure 19: Global Image-Guided Drug Delivery Market (Research Institutes and Universities), $Million, 2024-2035
  • Figure 20: Global Image-Guided Drug Delivery Market (Pharmaceutical and Biotechnology Companies), $Million, 2024-2035
  • Figure 21: Global Image-Guided Drug Delivery Market (Contract Research Organizations (CROs), $Million, 2024-2035
  • Figure 22: U.S. Image-Guided Drug Delivery Market, $Million, 2024-2035
  • Figure 23: Canada Image-Guided Drug Delivery Market, $Million, 2024-2035
  • Figure 24: U.K. Image-Guided Drug Delivery Market, $Million, 2024-2035
  • Figure 25: Germany Image-Guided Drug Delivery Market, $Million, 2024-2035
  • Figure 26: France Image-Guided Drug Delivery Market, $Million, 2024-2035
  • Figure 27: Italy Image-Guided Drug Delivery Market, $Million, 2024-2035
  • Figure 28: Spain Image-Guided Drug Delivery Market, $Million, 2024-2035
  • Figure 29: Rest-of-Europe Image-Guided Drug Delivery Market, $Million, 2024-2035
  • Figure 30: Japan Image-Guided Drug Delivery Market, $Million, 2024-2035
  • Figure 31: China Image-Guided Drug Delivery Market, $Million, 2024-2035
  • Figure 32: India Image-Guided Drug Delivery Market, $Million, 2024-2035
  • Figure 33: Australia Image-Guided Drug Delivery Market, $Million, 2024-2035
  • Figure 34: South Korea Image-Guided Drug Delivery Market, $Million, 2024-2035
  • Figure 35: Rest-of-Asia-Pacific Image-Guided Drug Delivery Market, $Million, 2024-2035
  • Figure 36: Data Triangulation
  • Figure 37: Top-Down and Bottom-Up Approach
  • Figure 38: Assumptions and Limitations

List of Tables

  • Table 1: Market Snapshot
  • Table 2: Global Image-Guided Drug Delivery Market (by Region), $Million, 2024-2035
  • Table 3: North America Image-Guided Drug Delivery Market (by Technology Type), $Million, 2024-2035
  • Table 4: North America Image-Guided Drug Delivery Market (by Application), $Million, 2024-2035
  • Table 5: North America Image-Guided Drug Delivery Market (by End User), $Million, 2024-2035
  • Table 6: U.S. Image-Guided Drug Delivery Market (by Technology Type), $Million, 2024-2035
  • Table 7: U.S. Image-Guided Drug Delivery Market (by Application), $Million, 2024-2035
  • Table 8: U.S. Image-Guided Drug Delivery Market (by End User), $Million, 2024-2035
  • Table 9: Canada Image-Guided Drug Delivery Market (by Technology Type), $Million, 2024-2035
  • Table 10: Canada Image-Guided Drug Delivery Market (by Application), $Million, 2024-2035
  • Table 11: Canada Image-Guided Drug Delivery Market (by End User), $Million, 2024-2035
  • Table 12: Europe Image-Guided Drug Delivery Market (by Technology Type), $Million, 2024-2035
  • Table 13: Europe Image-Guided Drug Delivery Market (by Application), $Million, 2024-2035
  • Table 14: Europe Image-Guided Drug Delivery Market (by End User), $Million, 2024-2035
  • Table 15: U.K. Image-Guided Drug Delivery Market (by Technology Type), $Million, 2024-2035
  • Table 16: U.K. Image-Guided Drug Delivery Market (by Application), $Million, 2024-2035
  • Table 17: U.K. Image-Guided Drug Delivery Market (by End User), $Million, 2024-2035
  • Table 18: Germany Image-Guided Drug Delivery Market (by Technology Type), $Million, 2024-2035
  • Table 19: Germany Image-Guided Drug Delivery Market (by Application), $Million, 2024-2035
  • Table 20: Germany Image-Guided Drug Delivery Market (by End User), $Million, 2024-2035
  • Table 21: France Image-Guided Drug Delivery Market (by Technology Type), $Million, 2024-2035
  • Table 22: France Image-Guided Drug Delivery Market (by Application), $Million, 2024-2035
  • Table 23: France Image-Guided Drug Delivery Market (by End User), $Million, 2024-2035
  • Table 24: Italy Image-Guided Drug Delivery Market (by Technology Type), $Million, 2024-2035
  • Table 25: Italy Image-Guided Drug Delivery Market (by Application), $Million, 2024-2035
  • Table 26: Italy Image-Guided Drug Delivery Market (by End User), $Million, 2024-2035
  • Table 27: Spain Image-Guided Drug Delivery Market (by Technology Type), $Million, 2024-2035
  • Table 28: Spain Image-Guided Drug Delivery Market (by Application), $Million, 2024-2035
  • Table 29: Spain Image-Guided Drug Delivery Market (by End User), $Million, 2024-2035
  • Table 30: Rest-of-Europe Image-Guided Drug Delivery Market (by Technology Type), $Million, 2024-2035
  • Table 31: Rest-of-Europe Image-Guided Drug Delivery Market (by Application), $Million, 2024-2035
  • Table 32: Rest-of-Europe Image-Guided Drug Delivery Market (by End User), $Million, 2024-2035
  • Table 33: Asia-Pacific Image-Guided Drug Delivery Market (by Technology Type), $Million, 2024-2035
  • Table 34: Asia-Pacific Image-Guided Drug Delivery Market (by Application), $Million, 2024-2035
  • Table 35: Asia-Pacific Image-Guided Drug Delivery Market (by End User), $Million, 2024-2035
  • Table 36: Japan Image-Guided Drug Delivery Market (by Technology Type), $Million, 2024-2035
  • Table 37: Japan Image-Guided Drug Delivery Market (by Application), $Million, 2024-2035
  • Table 38: Japan Image-Guided Drug Delivery Market (by End User), $Million, 2024-2035
  • Table 39: China Image-Guided Drug Delivery Market (by Technology Type), $Million, 2024-2035
  • Table 40: China Image-Guided Drug Delivery Market (by Application), $Million, 2024-2035
  • Table 41: China Image-Guided Drug Delivery Market (by End User), $Million, 2024-2035
  • Table 42: India Image-Guided Drug Delivery Market (by Technology Type), $Million, 2024-2035
  • Table 43: India Image-Guided Drug Delivery Market (by Application), $Million, 2024-2035
  • Table 44: India Image-Guided Drug Delivery Market (by End User), $Million, 2024-2035
  • Table 45: Australia Image-Guided Drug Delivery Market (by Technology Type), $Million, 2024-2035
  • Table 46: Australia Image-Guided Drug Delivery Market (by Application), $Million, 2024-2035
  • Table 47: Australia Image-Guided Drug Delivery Market (by End User), $Million, 2024-2035
  • Table 48: South Korea Image-Guided Drug Delivery Market (by Technology Type), $Million, 2024-2035
  • Table 49: South Korea Image-Guided Drug Delivery Market (by Application), $Million, 2024-2035
  • Table 50: South Korea Image-Guided Drug Delivery Market (by End User), $Million, 2024-2035
  • Table 51: Rest-of-Asia-Pacific Image-Guided Drug Delivery Market (by Technology Type), $Million, 2024-2035
  • Table 52: Rest-of-Asia-Pacific Image-Guided Drug Delivery Market (by Application), $Million, 2024-2035
  • Table 53: Rest-of-Asia-Pacific Image-Guided Drug Delivery Market (by End User), $Million, 2024-2035
  • Table 54: Rest-of-the-World Image-Guided Drug Delivery Market (by Technology Type), $Million, 2024-2035
  • Table 55: Rest-of-the-World Image-Guided Drug Delivery Market (by Application), $Million, 2024-2035
  • Table 56: Rest-of-the-World Image-Guided Drug Delivery Market (by End User), $Million, 2024-2035